logo
RFK Jr. ousts CDC's entire vaccine advisory committee

RFK Jr. ousts CDC's entire vaccine advisory committee

CBC5 hours ago

Social Sharing
U.S. Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the U.S. Centers for Disease Control and Prevention (CDC) on how to use vaccines and pledged to replace them with his own picks.
Major physicians and public health groups criticized the move to oust all 17 members of the Advisory Committee on Immunization Practices (ACIP).
Kennedy has not said who he would appoint to the panel, but said it would convene in just two weeks in Atlanta.
Although it's typically not viewed as a partisan board, the entire current roster of committee members were appointees of U.S. President Joe Biden's administration.
"Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028," Kennedy wrote in a Wall Street Journal opinion piece. "A clean sweep is needed to re-establish public confidence in vaccine science."
When reached by phone, the panel's now-former chair — Dr. Helen Keipp Talbot of Vanderbilt University — declined to comment. But another panel member, Noel Brewer at the University of North Carolina, said he and other committee members received an email late Monday afternoon that said their services on the committee had been terminated but gave no reason.
"I'd assumed I'd continue serving on the committee for my full term," said Brewer, who joined the panel last summer.
Brewer is a behavioural scientist whose research examines why people get vaccinated and ways to improve vaccination coverage. Whether people get vaccinated is largely influenced by what their doctors recommend, and doctors have been following ACIP guidance.
"Up until today, ACIP recommendations were the gold standard for what insurers should pay for, what providers should recommend, and what the public should look to," he said.
Committee not consulted
But Kennedy already took the unusual step of changing COVID-19 recommendations without first consulting the committee — a move criticized by doctors' groups and public health advocates.
"It's unclear what the future holds," Brewer said. "Certainly provider organizations have already started to turn away from ACIP."
Kennedy said the committee members had too many conflicts of interest. Currently, committee members are required to declare any potential such conflicts, as well as business interests, that arise during their tenure. They also must disclose any possible conflicts at the start of each public meeting.
But Dr. Tom Frieden, president and CEO of Resolve to Save Lives and former director of the CDC, said Kennedy's actions were based on false conflict-of-interest claims and set "a dangerous and unprecedented action that makes our families less safe" by potentially reducing vaccine access for millions of people.
"Make no mistake: Politicizing the ACIP as Secretary Kennedy is doing will undermine public trust under the guise of improving it," he said in a statement. "We'll look back at this as a grave mistake that sacrificed decades of scientific rigour, undermined public trust, and opened the door for fringe theories rather than facts."
'Not how democracies work'
Dr. Georges Benjamin, executive director of the American Public Health Association, called Kennedy's mass ouster "a coup."
"It's not how democracies work. It's not good for the health of the nation," he said.
Benjamin said the move raises real concerns about whether future committee members will be viewed as impartial. He added that Kennedy is going against what he told lawmakers and the public, and the public health association plans to watch Kennedy "like a hawk."
"He is breaking a promise," Benjamin said. "He said he wasn't going to do this."
Dr. Bruce A. Scott, president of the American Medical Association, called the committee a trusted source of science- and data-driven advice and said Kennedy's move, coupled with declining vaccination rates across the country, will help drive an increase in vaccine-preventable diseases.
The committee had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting.
During Kennedy's confirmation, Cassidy had expressed concerns about preserving the committee, saying he had sought assurances that Kennedy would keep the panel's current vaccine recommendations.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr. ousts CDC's entire vaccine advisory committee
RFK Jr. ousts CDC's entire vaccine advisory committee

CBC

time5 hours ago

  • CBC

RFK Jr. ousts CDC's entire vaccine advisory committee

Social Sharing U.S. Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the U.S. Centers for Disease Control and Prevention (CDC) on how to use vaccines and pledged to replace them with his own picks. Major physicians and public health groups criticized the move to oust all 17 members of the Advisory Committee on Immunization Practices (ACIP). Kennedy has not said who he would appoint to the panel, but said it would convene in just two weeks in Atlanta. Although it's typically not viewed as a partisan board, the entire current roster of committee members were appointees of U.S. President Joe Biden's administration. "Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028," Kennedy wrote in a Wall Street Journal opinion piece. "A clean sweep is needed to re-establish public confidence in vaccine science." When reached by phone, the panel's now-former chair — Dr. Helen Keipp Talbot of Vanderbilt University — declined to comment. But another panel member, Noel Brewer at the University of North Carolina, said he and other committee members received an email late Monday afternoon that said their services on the committee had been terminated but gave no reason. "I'd assumed I'd continue serving on the committee for my full term," said Brewer, who joined the panel last summer. Brewer is a behavioural scientist whose research examines why people get vaccinated and ways to improve vaccination coverage. Whether people get vaccinated is largely influenced by what their doctors recommend, and doctors have been following ACIP guidance. "Up until today, ACIP recommendations were the gold standard for what insurers should pay for, what providers should recommend, and what the public should look to," he said. Committee not consulted But Kennedy already took the unusual step of changing COVID-19 recommendations without first consulting the committee — a move criticized by doctors' groups and public health advocates. "It's unclear what the future holds," Brewer said. "Certainly provider organizations have already started to turn away from ACIP." Kennedy said the committee members had too many conflicts of interest. Currently, committee members are required to declare any potential such conflicts, as well as business interests, that arise during their tenure. They also must disclose any possible conflicts at the start of each public meeting. But Dr. Tom Frieden, president and CEO of Resolve to Save Lives and former director of the CDC, said Kennedy's actions were based on false conflict-of-interest claims and set "a dangerous and unprecedented action that makes our families less safe" by potentially reducing vaccine access for millions of people. "Make no mistake: Politicizing the ACIP as Secretary Kennedy is doing will undermine public trust under the guise of improving it," he said in a statement. "We'll look back at this as a grave mistake that sacrificed decades of scientific rigour, undermined public trust, and opened the door for fringe theories rather than facts." 'Not how democracies work' Dr. Georges Benjamin, executive director of the American Public Health Association, called Kennedy's mass ouster "a coup." "It's not how democracies work. It's not good for the health of the nation," he said. Benjamin said the move raises real concerns about whether future committee members will be viewed as impartial. He added that Kennedy is going against what he told lawmakers and the public, and the public health association plans to watch Kennedy "like a hawk." "He is breaking a promise," Benjamin said. "He said he wasn't going to do this." Dr. Bruce A. Scott, president of the American Medical Association, called the committee a trusted source of science- and data-driven advice and said Kennedy's move, coupled with declining vaccination rates across the country, will help drive an increase in vaccine-preventable diseases. The committee had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. During Kennedy's confirmation, Cassidy had expressed concerns about preserving the committee, saying he had sought assurances that Kennedy would keep the panel's current vaccine recommendations.

Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight

Globe and Mail

time6 hours ago

  • Globe and Mail

Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight

"Obesity Drugs Market" Obesity Companies such as Yuhan, Click Therapeutics, Novo Nordisk, ProQR Therapeutics, Bukwang Pharmaceutical, Empros Pharma, Boehringer Ingelhium, Rhythm Pharmaceuticals, BioRestorative Therapies, Hanmi Pharmaceuticals, Carmot Therapeutics, D&D Pharmatech, SCOHIA PHARMA, Nano Precision Medical, Terns Pharmaceuticals, Caliway Biopharmaceutics, Eli Lilly and Company, and others (Albany, USA) DelveInsight's 'Obesity Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Obesity market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Obesity market. Request for a Free Sample Report @ Obesity Market Forecast Some facts of the Obesity Market Report are: In March 2025, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery service, to ensure access to Wegovy® (semaglutide) injection in all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). This service offers uninsured patients or those with commercial insurance lacking obesity medicine coverage the option to purchase Wegovy® at a reduced cost of $499 per month. This initiative expands Novo Nordisk's efforts to meet the needs of individuals living with obesity, following the FDA's confirmation that the shortage of the medication has been resolved and that all doses now meet or exceed U.S. demand. In February 2025, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) vials for $499 through the Zepbound Self Pay Journey Program, alongside price reductions for 2.5 mg and 5 mg vials. These are available exclusively via LillyDirect Self Pay Pharmacy Solutions, offering direct savings outside of insurance. In February 2025, Amgen announced that the U.S. FDA has placed a hold on a study of the company's early-stage obesity candidate, AMG 513, marking another potential setback in its efforts to enter the growing weight loss drug market. Amgen has provided limited information about the drug, including its mechanism of action. In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial. However, the data also suggest that Eli Lilly's rival GLP-1 drug Zepbound may still have an advantage over Wegovy. In January 2025, Verdiva Bio Limited launched as a clinical-stage biopharmaceutical company focused on innovative therapies for obesity and cardiometabolic disorders. The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. In January 2025, Eli Lilly filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly's reply due by January 21. As per DelveInsight's estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7MM in 2023. DelveInsight's consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023. According to the findings, treatment rate for children was found to be less than that of adults across countries. Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany. The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others. On June 2023, Eli Lilly and Company (NYSE: LLY) announced the new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg). In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration. On June 2023, Pfizer (NYSE: PFE) updated that it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight loss treatments. On May 2023, Novo Nordisk (NYSE: NVO) announced positive results from a phase IIIa study, OASIS 1, in the global OASIS program for a once-daily oral formulation of semaglutide in obesity. Obesity Overview Obesity is a chronic condition characterized by an excessive accumulation of body fat, leading to adverse health effects and increased risk of various diseases. It is typically defined by a body mass index (BMI) of 30 or higher. Obesity results from complex interactions between genetic, environmental, socioeconomic, and behavioral factors. Sedentary lifestyles, high-calorie diets, and genetic predispositions contribute to its development. Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, hypertension, certain cancers, and musculoskeletal disorders. Additionally, it can impair quality of life and increase mortality rates. Prevention and management strategies for obesity include dietary modifications, regular physical activity, behavioral therapy, medications, and in severe cases, bariatric surgery. Public health initiatives and policies aimed at promoting healthy lifestyles and reducing obesity prevalence are essential to address this global epidemic and its associated health burdens. Learn more about Obesity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Obesity Market The Obesity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Obesity market trends by analyzing the impact of current Obesity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obesity market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Obesity market in 7MM is expected to witness a major change in the study period 2020-2034. Obesity Epidemiology The Obesity epidemiology section provides insights into the historical and current Obesity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool, trends, and assumptions. Explore more about Obesity Epidemiology @ Obesity Market Dynamics Obesity Drugs Uptake This section focuses on the uptake rate of the potential Obesity drugs recently launched in the Obesity market or expected to be launched in 2020-2034. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug. Obesity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Obesity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Obesity Pipeline Development Activities The Obesity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Obesity key players involved in developing targeted therapeutics. Request for a sample report to understand more about the Obesity pipeline development activities @ Obesity Medication and Approved drugs Obesity Therapeutics Assessment Major key companies are working proactively in the Obesity Therapeutics market to develop novel therapies which will drive the Obesity treatment markets in the upcoming years are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others. Learn more about the emerging Obesity therapies & key companies @ Obesity Clinical Trials and Advancements Obesity Report Key Insights 1. Obesity Patient Population 2. Obesity Market Size and Trends 3. Key Cross Competition in the Obesity Market 4. Obesity Market Dynamics (Key Drivers and Barriers) 5. Obesity Market Opportunities 6. Obesity Therapeutic Approaches 7. Obesity Pipeline Analysis 8. Obesity Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Obesity Market Table of Contents 1. Key Insights 2. Executive Summary 3. Obesity Competitive Intelligence Analysis 4. Obesity Market Overview at a Glance 5. Obesity Disease Background and Overview 6. Obesity Patient Journey 7. Obesity Epidemiology and Patient Population 8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices 9. Obesity Unmet Needs 10. Key Endpoints of Obesity Treatment 11. Obesity Marketed Products 12. Obesity Emerging Therapies 13. Obesity Seven Major Market Analysis 14. Attribute Analysis 15. Obesity Market Outlook (7 major markets) 16. Obesity Access and Reimbursement Overview 17. KOL Views on the Obesity Market 18. Obesity Market Drivers 19. Obesity Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store